- The impact of diabetes mellitus and HBV infection on major 1
- adverse cardiovascular events related to statin use for Chinese 2
- population with cardiovascular disease 3
- Running title: Effect of DM or HBV infection on MACEs. 4
- Qian Wu<sup>a</sup>, MM; Xiaoxuan He<sup>a</sup>, MM; Xiaoning Tong<sup>a</sup>, MM; Ying Li<sup>b</sup>, MM; Xiaoqin 6
- Wang<sup>a</sup>, MD 7

12

14

18

- <sup>a</sup>Department of Clinical Laboratory, The First Affiliated Hospital of Xi'an Jiaotong 8
- University, Xi'an, 710061, Shaanxi Province, China. 9
- <sup>b</sup>Department of Clinical Laboratory, Shaanxi Kang Fu Hospital, Xi'an,710065, 10
- Shaanxi Province, China. 11
- Qian Wu and Xiaoxuan He contributed equally to this work. 13
- Correspondence to: Dr. Xiaoqin Wang, M.D. Department of Clinical Laboratory, 15
- The First Affiliated Hospital of Xi'an Jiaotong University, No. 277 West Yanta Road, 16
- Xi'an 710061, Shaanxi Province, China. E-mail: wq710641296@xjtufh.edu.cn. 17
- **Clinical Perspective** 19
- 20 What Is New?
- 21 • This study investigates the association between statin therapy and major adverse
- cardiovascular events (MACEs) in Chinese patients with cardiovascular disease who 22
- have concurrent hepatitis B virus infection or diabetes mellitus. 23
- 24 • The findings suggest potential cardiovascular benefits of statin therapy in this

NOTE Prints preprint population that has not been certified by peer review and should not be used to guide clinical practice.

- The study explores the relationship between statin use and changes in hepatic 26
- function, atherosclerotic markers, and inflammatory parameters. 27

#### What Are the Clinical Implications? 28

- The results provide evidence supporting statin use in cardiovascular disease patients 29
- 30 with hepatitis B virus infection or diabetes mellitus.
- Glycemic control appears to be an important factor in optimizing cardiovascular 31
- outcomes in these patients. 32
- Regular monitoring of hepatic and inflammatory markers may be valuable in 33
- 34 assessing treatment response.

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

**BACKGROUND:** The association between hepatitis B virus (HBV) infection, diabetes mellitus (DM) and cardiovascular disease (CVD) remains uncertain. This study was aimed to investigate the impact of HBV infection and DM on 13 major adverse cardiovascular events (MACEs) among CVD patients with or without statin use. METHODS AND RESULTS: In total, 45,013 individuals participated in the baseline survey between June 2020 and August 2023. The patients were categorized into two groups according to their surface antigen status. Finally, a sample size of 496 participants was included in the study: patients with coexisting CVD and HBV (n = 225) and patients with CVD alone (n = 271). The implementation of statins has demonstrated the potential to reduce the incidence of coronary heart disease (CHD) and angina pectoris (AP) in individuals with CVD who are also affected by HBV infection. The analysis of stratification, taking into account the presence of DM, has demonstrated a significant increased vulnerability to myocardial infarction (MI), acute myocardial infarction (AMI), and heart failure (HF) among individuals with HBV infection combined with CVD. DM and hemoglobin A1c (HBA1c) level of  $\geq$  6 are identified as risk factors for the development of CHD, MI, AP, and hypertension. Our study also suggests that statin therapy led to a dose-dependent decrease in liver fibrosis, as well as improvement of the atherogenicity index and systemic inflammatory response in patients with CVD. CONCLUSION: Our study indicates that CVD patients who also have HBV infection or DM may experience a reduction in MACEs when treated with statins. Furthermore, our research indicates that focusing on long-term glycemic control is essential in this patient population in order to enhance cardiovascular outcomes. The observed improvements in hepatic function, atherosclerotic burden, and systemic inflammation associated with statin therapy may contribute

to the favorable cardiovascular outcomes among individuals with CVD.

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

**Key Words:** HBV ■ diabetes mellitus ■ CHD ■ cardiovascular disease ■ statins use Coronary heart disease (CHD) is the primary cause of mortality in humans, accounting for approximately 9 million deaths annually worldwide <sup>1</sup>. CHD encompasses cardiovascular conditions resulting from the narrowing or obstruction of the coronary arteries due to atherosclerosis, as well as myocardial ischemia, hypoxia, or necrosis caused by functional alterations in these arteries <sup>2</sup>. Presently, there exists a prevailing belief within the academic community that the presence of obesity, smoking, and alcohol consumption plays a substantial role in the advancement of CHD <sup>3, 4</sup>. Furthermore, it is worth emphasizing that hypertension, hyperlipidemia, hypercholesterolemia, and diabetes mellitus (DM) also contribute to the development of CHD <sup>5-8</sup>. Notably, DM represents a significant risk factor, as the elevated blood glucose levels experienced by individuals with this condition often induce oxidative stress and inflammatory harm, ultimately resulting in atherosclerosis, coronary artery dysfunction, myocardial infarction, and cellular impairment, thereby fostering the progression of CHD 9. DM is additionally linked to an unfavorable long-term prognosis in individuals diagnosed with CHD. In comparison to patients without DM, those with DM complicated by CHD exhibit a higher mortality rate over a span of 10 years <sup>10</sup>. The global prevalence of Hepatitis B virus (HBV) infection is substantial, rendering it a significant concern for public health. Prolonged HBV infection can result in chronic hepatitis, cirrhosis, liver decompensation, and hepatocellular carcinoma <sup>11</sup>. Chronic HBV infection is characterized by a state of inflammation, which has been observed

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

to elevate the likelihood of major adverse cardiovascular events (MACE) and cerebrovascular disease in other conditions featuring chronic low-grade inflammation 12, 13. Several studies have examined the association between HBV infection and cardiovascular disease (CVD); however, the findings have been inconclusive 14-17. Certain studies have identified a positive correlation between HBV infection and coronary artery disease <sup>17</sup>, whereas others have indicated a negative correlation <sup>14-16</sup>. In individuals diagnosed with chronic viral hepatitis, it has been observed that those with HCV infection exhibit a notably elevated susceptibility to composite arterial events and all-cause mortality when compared to those with HBV infection <sup>18, 19</sup>. Furthermore, investigations have indicated that there is no substantial association between the prevalence of macrovascular complications, microvascular complications of diabetes, diabetic ketosis, or diabetic ketoacidosis and the status of HBV infection <sup>20</sup>. Hence, it is crucial to persist in the examination of the correlation between HBV infection and MACE. Statins have demonstrated efficacy in mitigating the occurrence of CVD and are endorsed as the primary therapeutic approach for hypercholesterolemia in clinical guidelines <sup>21, 22</sup>. The American College of Cardiology/American Heart Association guidelines for managing blood cholesterol levels to minimize the risk of atherosclerotic CVD (ASCVD) in adults have classified statins into low, moderate, and high potency categories, based on comprehensive analysis of their lipid-lowering effects across various clinical trials and direct comparisons. High-potency statins, such as rosuvastatin at doses of 20 mg/d and 40 mg/d, and atorvastatin at doses of 40

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

mg/d and 80 mg/d, have exhibited a noteworthy decrease in low-density lipoprotein cholesterol (LDL-C) levels surpassing 50% <sup>21</sup>. Additionally, decreased cholesterol levels by statin use may impact the advancement of hepatic fibrosis by ameliorating portal hypertension and reducing the excessive accumulation of hepatic triglycerides 23-25. Numerous clinical studies have demonstrated the efficacy of statin administration in patients with NAFLD, leading to improvements in liver ultrasonography and liver function tests <sup>26-28</sup>. The independent association of statin use with reductions in hepatic steatosis and fibrosis stage in NAFLD patients has also been observed <sup>26, 28</sup>. The pathogenesis of hepatic fibrosis is characterized by a multifaceted interaction between lipid metabolism and systemic chronic inflammatory response in patients with CVD <sup>29, 30</sup>. Hence, this study aimed to gather data on patients with both HBV and CVD, as well as those with CVD alone, in order to examine the correlation between statin use and HBV infection, DM, or hemoglobin A1c (HbA1c) levels among individuals with CVD. Additionally, the study sought to assess the impact of HBV infection, DM, HbA1c levels, or statin use on various cardiovascular outcomes in patients with CVD. Currently, there is uncertainty regarding the impact of statins on hepatic fibrosis and systemic inflammatory response, as well as their effects on CVD and lipid metabolism. The identification of specific markers in this context remains ambiguous. It is our assertion that the identification of suitable markers is crucial for the monitoring of liver fibrosis and systemic inflammation in patients with CVD undergoing statin therapy. Our research aimed to assess the impact of statin therapy on hepatic fibrosis, systemic inflammation, and atherogenic indices in patients with

CVD.

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

# MATERIALS AND METHODS

## Study design and participants

A prospective cohort study was conducted to examine the prevalence, incidence, and associated factors, such as HBV infection, in relation to CVD. The study was approved by the Ethics Committee of the First Affiliated Hospital of Xi'an Jiaotong University (No:XJTU1AF2024LSYY-054). In total, 45,013 individuals participated in the baseline survey at the First Affiliated Hospital of Xi'an Jiaotong University (Xi'an, China) between June 2020 and August 2023. Of these, 43,750 cases were excluded due to HCV, HIV, syphilis infection, as well as incomplete basic data of test results and medical records. A total of 268 patients presenting with hepatic hemangioma, toxic diffuse goiter with hyperthyroidism, hypothyroidism, endometrial cancer, stage 5 hemodialysis status of chronic kidney disease, chronic renal insufficiency, skull osteoma, and right lobe cyst of thyroid gland were excluded from the study. Additionally, 499 cases with incomplete test data, including five quantitative variables (disease load, blood cells, blood lipid, and other information), as well as incomplete drug use information, were also excluded. Consequently, a final sample size of 496 participants was included in the study (refer to Figure 1). The patients were categorized into two groups according to their surface antigen status: patients with coexisting CVD and HBV (n = 225) and patients with CVD alone (n = 271). In addition, a sample size of 494 CVD participants was included, patients with statin use (n = 415) and statin-free (n = 79), to investigate the effect of statin use on hepatic

### **Clinical data collection and measurements**

fibrosis, atherosclerotic burden, and systemic inflammation.

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

The variables considered in this study encompassed patient demographics such as age and gender, as well as medical factors including hypertension, smoking/alcohol consumption, diabetes, disease status, biochemical indicators, blood cell indicators, HBV five-item quantitative, HBV-DNA quantitative, statin use, antiviral therapy for hepatitis B, and major adverse cardiovascular events. The ratios of platelet count to lymphocyte count (PLR) and neutrophil count to lymphocyte count (NLR) are computed to assess certain adverse cardiovascular events, such as recurrent angina pectoris (AP), hospitalization for unstable angina pectoris (UAP), acute myocardial infarction (AMI), severe arrhythmia, heart failure (HF), and death due to CHD. Major adverse cardiovascular events include recurrent AP, UAP requiring hospitalization, AMI, severe arrhythmia, HF, coronary-related death, etc. Secondary adverse cardiovascular events include Killip classification II-IV or NYHA Classification II-IV. All specimens were tested within 2 hours following their collection. In cases where immediate testing was not feasible, specimens were stored at a temperature of -20°C for a duration not exceeding 2 days. The fluorescence quantitative PCR detection of HBV-DNA load was conducted utilizing the 7500 fluorescence quantitative PCR instrument and associated reagents (ABI, USA). Quantitative determination of biochemical indicators was performed using the Roche AU5600 automatic

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

biochemical analyzer and its corresponding original reagents. The quantification of the five components of serum hepatitis B was performed using the i2000sr instrument manufactured by Abbott Laboratories, USA. The detection of blood cell indicators was conducted using the routine automatic flow cytometer Mindray CAL8000. The Roche E801 automatic immunoassay analyzer, along with original reagents, was utilized for the quantitative determination of B-type natriuretic peptide (BNP) in the anterior brain. HbA1c was assessed with high-performance liquid chromatography. All aforementioned measurements were performed in accordance with the manufacturer's instructions. Calculations of the albumin-bilirubin index (ALBI) score, fibrosis 4 index (FIB-4) index, complete blood count derived inflammation index (CBCIIs) and atherogenic indices. Non-invasive and non-destructive testing markers, including FIB-4, ALBI, CBCIIs, such platelet monocyte and as (PMR), neutrophil/lymphocyte ratio (NLR), SII, systemic inflammatory response index (SIRI), and aggregate index of systemic inflammation, and atherogenic indices, such as atherogenic index of plasma (AIP), atherogenic index (AI), Castelli risk index-I (CRI-I), Castelli risk index-II (CRI-II), and triglyceride-rich lipoprotein cholesterol (TRL-C) were used to evaluate the effects of statin use on hepatic fibrosis, systemic inflammation, and arteriosclerotic degree in patients with CVD. The calculation formulas of hepatic fibrosis indicators ALBI score, FIB-4 index were measured as described previously <sup>31</sup>. CBCIIs, including SIRI, SII, aggregate index of systemic inflammation (AISI), SIRI/HDL-C, and SIRI×LDL-C, were calculated as described

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

previously <sup>32, 33</sup>. Atherogenic indices, such as adjusted AIP, AIP, AI, CRI-II, LCI, and TRL-C, were calculated as described previously <sup>34-37</sup>. **Statistical analysis** In the case of measurement data that conforms to a normal distribution, the mean  $\pm$ standard deviation is employed for representation, and intergroup comparison is carried out through the utilization of a t-test. Conversely, for measurement data that does not adhere to a normal distribution, the median (quartile) [M  $(P_{25} \sim P_{75})$ ] is employed for representation, and intergroup comparison is conducted using the Mann-Whitney U non-parametric test. Count data is represented using frequency and percentage (%), and intergroup comparison is performed using either the chi-square test or Fisher's exact probability method. The Breslow-Day test is employed for conformance testing in hierarchical analysis, while the Mantel-Haenszel test is utilized for hierarchical chi-square testing. To address potential confounding, logistic regression models were used to estimate the odds ratio (OR) and 95% CI for MACE. All statistical analyses were conducted using SPSS, version 22.0 (SPSS Inc, USA). A 2-tailed P value of less than 0.05 was considered to be statistically significant. **RESULTS** Table 1 presents the demographic characteristics of the study participants. A total of 496 subjects were included in the analysis, comprising 225 individuals with pure CVD and 271 individuals with CVD accompanied by HBV infection. Notably, the CVD combined with HBV infection group exhibited a statistically significant increase

in the proportion of males and AMI when compared to the CVD alone group (both P

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

< 0.05). Furthermore, when comparing patients with CVD alone to those with CVD combined with HBV, it was observed that the latter group exhibited elevated levels of HBsAg, HbsAb, and HbcAb (all P < 0.05). Conversely, the CVD combined with HBV group displayed lower levels of weight, medication dosage, TG, Lpa, PLR, and PLT in comparison to the CVD alone group. Additionally, the proportions of diabetes and pre-hospital medication were relatively lower in the CVD combined with HBV group. Notably, the remaining indicators presented in Table 1 did not demonstrate statistical significance. The quantitative (Supplementary table 1) and qualitative (Supplementary table 2) baseline characteristics and statistical comparisons of individuals with CVD who were either using or not using statins were also documented. It is evident that there are statistically significant differences in height, weight, platelet count, alanine aminotransferase levels, and aspartate aminotransferase levels among the three groups (all P < 0.05). The utilization of statins resulted in lower TG (P = 0.000), LDL-C (P = 0.000), ApoB (P = 0.000), and non-HDL-C (P = 0.000) 0.000) levels. Based on the findings presented in Supplementary table 2, it is evident that there exist statistically significant disparities in gender, diabetes, and smoking history across the three groups, with or without statin usage (all P < 0.05). It is worth noting that long-term use of statins has been associated with an increased risk of DM <sup>38</sup>. Consequently, clinicians may be avoiding prescribing statins to cardiovascular patients with diabetes, leading to a higher proportion of non-statin use in this population (65.8%). Conversely, no statistically significant variations were observed in hypertension, alcohol history, and anti-HBV treatment among the three groups (all

P > 0.05).

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

Relationship of Statin Use with HBV Infection and Quantification. To examine the relationship between statin use and HBV infection, we conducted a study comparing HBV infection rates and quantitative parameters in patients both with and without statin use. Our analysis revealed a significant association between statin use and HBV infection rates ( $\chi^2 = 76.835$ , P = 0.000). Subsequent pairwise comparisons demonstrated that the HBV infection rate in the group not using statins was 97.5% (77/79), whereas the rate in the group using atorvastatin 20 mg was 40.4% (91/225), indicating a protective effect with an OR of 0.018 (95% CI: 0.004 - 0.074). In the rosuvastatin 10 mg group, the HBV infection rate was 53.7% (102/190), indicating a potential protective effect with an OR of 0.030 (95% CI: 0.007 - 0.126). Furthermore, the HBV infection rate was 40.4% (91/225) in the atorvastatin 20 mg group and 53.7% (102/190) in the rosuvastatin 10 mg group, demonstrating a statistically significant difference between the two groups (P = 0.002). This suggests that the HBV infection rate in the rosuvastatin 10mg group was relatively higher, with an odds ratio of 1.94 (95% CI: 1.28 - 2.94) (**Table 2**). The HbsAg levels ranged from less than 0.05 to 250, the Median Difference (0-1) was calculated to be 70 (95% CI: 26 to 125). Additionally, the Median Difference (0-2) was found to be 63 (95% CI: 18 to 117). These findings indicate that the quantification of HbsAg in individuals using statins is notably reduced compared to those not using statins (Table 3). The analysis of the Median Difference (1-2) yielded a value of 0 (95% CI: 0 to 0), suggesting a lack of statistically significant disparity in the effectiveness of the two statins in reducing

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

HbsAg quantitation. However, the OR (atorvastatin/rosuvastatin) in Table 2 was calculated as 1.94 (95% CI: 1.28 to 2.94), indicating a lower infection rate associated with atorvastatin (Table 3). This apparent contradiction underscores the need for a nuanced interpretation that considers both qualitative and quantitative aspects of the investigation. Furthermore, when compared to the group not using statins, the quantification of HBV-DNA and HBcAb was significantly lower in the statins use group. Conversely, the quantification of HBsAb, HBeAg, and HBeAb was significantly higher in the statins use group (Table 3). In addition, Table 4 demonstrates a significant dose-effect relationship between statin dosage and HbsAg quantification (P = 0.000), indicating that higher doses result in lower HbsAg levels, with the exception of a slight rebound observed at the highest dose of rosuvastatin 20 mg. Nevertheless, the limited sample size at this dosage level necessitates further validation of these findings. The impact of HBV infection, stratified by statins use, on multiple clinical outcomes among CVD patients. In our study, atorvastatin and rosuvastatin emerge as the prevailing lipid-lowering medications, with atorvastatin 20 mg and rosuvastatin 10 mg serving as the primary drug dosage combinations. This particular combination is employed as a stratification factor to examine the impact of HBV infection on 13 clinical outcomes among individuals with CVD. According to the findings depicted in Figure 2, it was observed that HBV infection exhibited a protective effect on the occurrence of CHD (OR = 0.27, 95% CI: 0.12 - 0.60; P = 0.001) and AP (OR = 0.56, 95% CI: 0.36 - 0.86; P = 0.008). Conversely, HBV infection was identified as a risk

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

factor for AMI (OR = 2.24, 95% CI: 1.40 - 3.57; P = 0.001). Furthermore, it was determined that HBV infection did not significantly impact the remaining 11 clinical outcomes in individuals with CAD. The impact of HBV infection, stratified by DM, on multiple clinical outcomes among CVD patients. Given that the prevalence of DM among patients with and without HBV infection was 48.7% and 62.7%, respectively (P = 0.002; Table 1), it is evident that the baseline characteristics were not equivalent. Consequently, the presence of DM may exert an influence on cardiovascular outcomes. In this study, DM was employed as a stratified variable to examine the potential impact of HBV infection on clinical outcomes in patients with CVD. The results of our study indicate that the coexistence of DM and HBV infection may significantly increase the risk of AMI (OR = 5.37, 95% CI: 2.91 - 9.92; P < 0.001) as well as unfavorable secondary clinical outcomes (OR = 4.34, 95% CI: 2.06 - 9.15; P < 0.001) (Figure 3). These findings suggest the importance of implementing strict blood sugar control and anti-HBV therapy in patients with this comorbidity. The impact of DM and HbA1c ( $\geq 6\%$  or < 6%) on multiple clinical outcomes among CVD patients. Based on the baseline characteristics of the population statistics, a comprehensive analysis was conducted on a total of 496 individuals, comprising 273 subjects with DM and 223 subjects without DM. The findings revealed that, in comparison to the non-DM group, the DM group exhibited a notably higher prevalence of hypertension history and the administration of atorvastatin 20 mg dosage (both P < 0.05). Conversely, the prevalence of smoking history,

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

rosuvastatin 10 mg dosage, and overall statin usage were significantly lower in the DM group (all P < 0.05). Furthermore, in comparison to the non-DM group, the DM group exhibited elevated levels of MO, NE, MHR, NHR, BNP, ALS, and HbA1c (all P < 0.05). Conversely, the DM group displayed a relatively diminished ApoE level when contrasted with the non-DM group. There were no statistically significant differences observed in various demographic and clinical factors, including age, gender, height, weight, BMI, alcohol consumption history, LDL-C level, TG level, HDL-C level, triglyceride-to-HDL-C ratio, ApoA level, ApoB level, Lp(a) level, TC level, non-HDL-C level, CYS-C level, LY count, PLT count, NLR, PLR, AST/ALT, AST level, TBil level, and ALP level, between the two groups (Supplementary table 3 and 4). As shown in Figure 4, DM poses a significant risk for CHD (RO = 6.9, 95% CI: 3.2-14.9; P < 0.001) among patients with CVD, MI (RO = 2.2, 95% CI: 1.5-3.2; P< 0.001), AP patients who were not prescribed statins prior to admission (RO = 3.5, 95% CI: 1.3-9.3; P = 0.01), and individuals with hypertension extreme risk (RO = 2.9, 95% CI: 2.0-4.2; P < 0.001). Among patients who were not prescribed statins prior to admission, those with HbA1c levels  $\geq$  6 exhibited the highest susceptibility to CHD, as indicated by an OR of 34.4 (95% CI: 4.2 to 283.6). However, it is important to note that the OR results displayed significant variability due to the limited sample size of the CHD group, which consisted of only 14 cases (Figure 5). In addition, HbA1c levels  $\geq 6$  also be recognized as a significant risk factor of AP patients who were not prescribed statins prior to admission (RO = 1.6, 95% CI: 1.1-2.3; P = 0.019) and individuals with hypertension extreme risk (RO = 2.7, 95% CI: 1.9-4.1; P < 0.001;

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

Figure 5). Comparison of the effects of atorvastatin and rosuvastatin on multiple clinical outcomes in patients with CVD. The Supplementary table 5 presents a comparison of the effects of atorvastatin and rosuvastatin on 13 clinical outcomes in patients diagnosed with CVD. In comparison to patients prescribed atorvastatin, those prescribed rosuvastatin exhibited the higher susceptibility to CHD and CCU, with OR values of 2.1 (95% CI: 1.0 to 4.2; P = 0.047) and 4.1 (95% CI: 2.5 to 6.6; P < 0.001), respectively. Additionally, the proportion of patients with NYHA classification and a lower risk of UAP were 0.51 (95% CI: 0.32 to 0.79; P = 0.003) and 0.62 (95% CI: 0.39 to 0.99; P = 0.043), respectively. In comparison to atorvastatin, the administration of rosuvastatin resulted in a statistically significant decrease in the median duration of hospitalization by one day, with a 95% CI ranging from 0.0 to 1.0 day (P = 0.001; Supplementary table 6). Interaction of statin use with hepatic FIB-4, complete blood count-derived inflammation indexes (CBCIIs) or ALBI grade. The baseline characteristics and statistical comparisons of both quantitative (Supplementary table 7) and qualitative (Supplementary table 8) parameters of individuals with CVD were using or not using statins. Significant differences were observed in height, weight, platelet count, ALT levels, and AST levels among the three groups (all P < 0.05). The use of statins led to a significant decrease in levels of TG, LDL-C, ApoB, and non-HDL-C (all P = 0.000) (Supplementary table 7). Analysis of the data in Supplementary table 8 reveals statistically significant differences in gender, diabetes, and smoking history

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

among the three groups (all P < 0.05). In order to assess the potential impact of statin use on improving clinical outcomes related to CVD by inhibiting the progression of liver fibrosis, we conducted a study to examine the association of different statin drugs and doses with FIB-4 levels in patients with CVD. The findings of our study demonstrated that atorvastatin was associated with lower FIB-4 levels in comparison to non-statin users, whereas rosuvastatin did not exhibit a significant difference in FIB-4 levels compared to non-statin users (Supplementary table 9). Our study also revealed that the use of statins was associated with a reduction in the levels of SIRI and SIRI/HDL-C, while also leading to an increase in PMR and SII in patients with CVD (Supplementary table 9). The findings of dose-stratification analysis in CVD patients revealed a correlation between the increased dosage of atorvastatin and rosuvastatin and the reduction in FIB-4 levels, suggesting the presence of a dose-response relationship (Supplementary table 10). Concurrently, a FIB-4 stratification analysis was conducted, revealing that patients treated with atorvastatin exhibited a higher proportion of FIB-4 < 1.45 and a lower proportion of FIB-4 > 3.25. Nevertheless, the reduction in FIB-4 level with rosuvastatin was not as pronounced as with atorvastatin (Supplementary table 11). The ALBI grade is a liver function assessment tool that utilizes measurements of albumin and bilirubin levels. The study examined the impact of statin medications on liver function markers and ALBI grade. Statin use was found to significantly decrease DBIL levels compared to non-statin users, while showing no significant effect on other liver function indices, including ALBI grade (Supplementary table 12).

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

Stratified analysis based on ALBI grade revealed that none of the patients progressed to an ALBI grade  $\geq$ -1.39, indicative of the group with the poorest prognosis. Furthermore, statin drug use did not influence ALBI grade in the remaining two groups (Supplementary table 13). Effect of statin use on atherogenic indices. As shown in Supplementary table 14, In comparison to statin-free group, the group with statin use exhibited a significant decrease in levels of AI, CRI-II, CRI-II, and LCI, whereas adjusted AIP, AIP, and RLP-C did not show a statistically significant difference. **DISCUSSION** In our study, the baseline data analysis revealed that individuals with both HBV and CVD exhibited notably reduced levels of TG and Lp(a) compared to those with CVD alone. This observation could potentially be attributed to the varying prevalence of diabetes and the utilization of statins among the patient population. Consequently, it is imperative to stratify the HBV cohort based on their statin and diabetes risk profiles in order to comprehensively assess the diverse clinical outcomes in patients with CVD. The utilization of statins has the capacity to diminish the prevalence of CHD and AP among individuals with CVD associated with HBV infection. Stratification analysis, considering the presence of DM, revealed a notably heightened susceptibility to MI, AMI, and HF in patients with HBV infection combined with CVD. These findings imply that CVD patients with HBV infection should judiciously employ statins and effectively manage blood glucose levels. HBV infection has the potential to give rise to a range of intrahepatic and extrahepatic

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

ailments, encompassing acute and chronic hepatitis, cirrhosis, hepatocellular carcinoma, metabolic syndrome, CVD, and renal injury <sup>39-41</sup>. The pathogenesis of HBV infection is intricate and multifaceted, essentially manifesting as a multisystem disorder. The underestimation of the influence of HBV infection on atherosclerosis has been observed in academic research. Multiple studies have demonstrated that the inflammation triggered by HBV infection serves as a significant contributing factor to the development of atherosclerosis. Conversely, atherosclerosis also exerts subsequent effects on the severity of chronic HBV infection, thereby establishing a detrimental cycle <sup>17</sup>. In patients concomitant HBV and MAFLD decreases the risk of ASCVD when compared with MAFLD alone, which may attribute to antiviral treatment <sup>41</sup>. The findings of present studies <sup>17, 41</sup> and our research indicate that the implementation of either antiviral therapy or lipid-lowering statin therapy holds the potential to improve liver metabolism or liver injury, consequently reducing the susceptibility to CVD associated with HBV infection. Our study revealed that HBV infection posed a significant risk for AMI in patients with CVD (OR = 2.24, 95% CI: 1.40-3.57; P = 0.001). However, our findings did not indicate a significant association between HBV infection and MI (OR = 1.08, 95%CI: 0.69-1.68; P=0.815). Analysis of baseline data demonstrated that the proportion of AMI in patients with both HBV infection and CVD was 39.1% (106/271), which was significantly higher than the proportion in patients with CVD alone (23.1%) (52/225; P < 0.001). Currently, there is a lack of pertinent research indicating that HBV infection serves as a risk factor for AMI. Furthermore, the underlying physiological

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

and pathological mechanisms by which HBV infection may contribute to an increased risk of AMI in patients with CVD remain unclear. It is plausible that our findings may be attributed to potential data bias, as we did not conduct a multivariate regression analysis. Moreover, a comprehensive epidemiological investigation with larger sample sizes is necessary to ascertain the risk of HBV infection in relation to AMI. According to a comprehensive survey of over 90,000 individuals, patients with HBV and DM was found to be associated with significantly reduced risks of MI (aHR = 0.49; 95% CI: 0.42 to 0.56), ischaemic stroke (aHR = 0.61; 95% CI: 0.56 to 0.67), HF (aHR = 0.50; 95% CI: 0.43 to 0.59), and all-cause mortality (aHR = 0.72; 95% CI:0.70 to 0.75) when compared to DM alone <sup>14</sup>, while the researchers did not provide a specific explanation. Hence, the association between enhanced liver metabolism through antiviral therapy in patients with HBV and its potential correlation with MACE, HF, and all-cause mortality remains uncertain. In our study, the findings of risk stratification based on DM indicate that HBV infection is associated with a decreased risk of CDH in patients with CVD (OR = 0.32, 95% CI: 0.15-0.68; P =0.004). However, when HBV infection is combined with DM, it is associated with an increased risk of MI (OR = 2.12, 95% CI: 1.30 - 3.45; P = 0.002), AMI (OR = 5.37, 95% CI: 2.91 - 9.92; P < 0.001), and HF (OR = 2.58, 95% CI: 1.32 - 5.04; P = 0.005). These findings indicate that the clinical consequences linked to HBV infection in individuals with DM may have both positive and negative implications, contingent upon various confounding variables including the patient's baseline characteristics, antiviral therapy, diabetes management, and statin administration.

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

Furthermore, a comprehensive analysis was conducted on a cohort of 496 patients diagnosed with CVD to examine the variations in clinical and biochemical markers between individuals with CVD and DM and those without DM. Additionally, the impact of HbA1c levels and DM on various clinical outcomes in patients with CVD was investigated. Moreover, the effects of atorvastatin and rosuvastatin on multiple clinical outcomes in individuals with CVD were also examined. The correlation between DM and the extent of CVD has been examined in prior populations <sup>42</sup>. The investigation revealed that DM is linked to a greater occurrence of cardiogenic shock, more severe stenosis ( $\geq 70\%$ ) segments, and a higher frequency of complications <sup>43</sup>. A recent study encompassed a sample of 23,643 individuals who underwent consecutive coronary CT angiography. In comparison to non-DM patients, those with diabetes exhibited a heightened prevalence of obstructive CAD, characterized by more pronounced stenosis in both the proximal and middle segments of the coronary arteries 44. HbA1c serves as a precise diagnostic marker for diabetes, enabling the assessment of average blood sugar levels over a span of 2-3 months, while remaining minimally influenced by acute illnesses. Moreover, it holds the potential to inform treatment decisions. Subjects with HbA1c levels ranging from 5.7% to 6.4% exhibited elevated levels of coronary artery calcium and carotid intima-media thickness compared to subjects with HbA1c levels below 5.7%, suggesting that an increase in HbA1c levels is linked to an augmented burden of coronary and peripheral atherosclerosis in non-diabetic individuals with normal fasting glucose 45. A significant correlation was observed between the decrease in HbA1c levels and the

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

reduction in HR for MACE <sup>46</sup>. The meta-regression analysis further demonstrated that the mitigation of cardiovascular events among adult individuals with DM can be partially attributed to a decrease in HbA1c levels <sup>47</sup>. Patients diagnosed with T2DM who exhibit inadequate control of their HbA1c levels (ranging from 8% to 8.9% and equal to or greater than 9%) are found to have comparable or elevated mortality risks when compared to patients diagnosed with CVD <sup>48</sup>. Consequently, it is imperative to prioritize achieving optimal HbA1c levels in order to effectively mitigate risks, prevent mortality, and manage complications associated with DM. The results of our study indicate that elevated HbA1c levels and the presence of DM have a significant influence on various clinical outcomes among individuals diagnosed with CVD. Specifically, our findings demonstrate that individuals with DM and HbA1c levels  $\geq$  6% are at an increased risk for developing CHD, experiencing MI, AP, and hypertension. Furthermore, our study examined the impact of both atorvastatin and rosuvastatin on various clinical outcomes among individuals diagnosed with CVD. Notably, patients administered rosuvastatin exhibited the greatest susceptibility to CHD and admission to the CCU, accompanied by elevated rates of NYHA classification. Conversely, these individuals experienced a diminished likelihood of developing UAP. The findings of our study suggest an association between statin use and a decreased risk of HBV infection, potentially due to the inhibitory effects of statins on HBV-DNA replication or clearance. It may be prudent to consider reducing or discontinuing statin therapy in patients with HBV infection who exhibit transaminase

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

levels exceeding three times the upper limit of normal. Hence, it is important to acknowledge the potential for bias in this conclusion. Additionally, the administration of anti-HBV therapy to patients with HBV infection could potentially impact the outcome. The quantification of HBV infection in this study was based on HBsAg levels, and while statin use may reduce HBV-DNA levels until they become undetectable, it is unlikely to result in clearance of HBsAg. Multiple studies have documented the potential of statins to decrease the likelihood of advancing to cirrhosis and hepatocellular carcinoma in individuals with HBV infection <sup>49-54</sup>. This is attributed to the inhibition or eradication of HBV, which is believed to impede the progression to cirrhosis and liver cancer. Klundert et al. <sup>54</sup> discovered that statins inhibit the replication of the hepatitis B virus and decrease the viability of hepatoma cells by disrupting Rho-GTPases. Our findings align with this consensus. Furthermore, the HBV viral load remains relatively constant in the absence of effective anti-HBV treatment, suggesting that factors other than statins have minimal impact. Therefore, it is plausible to infer that the proposition of statins inhibiting or eradicating HBV is likely valid. To delve deeper into the potential mechanisms of statin therapy in CVD patients to improve clinical outcomes, we conducted additional research on the impact of statin therapy on hepatic function, atherosclerotic burden, and systemic inflammation. The importance of FIB-4 and ALBI grade as the non-invasive indicators for liver fibrosis in predicting CVD among patients with liver diseases or DM has been well documented <sup>55-59</sup>. Schonmann et al. <sup>58</sup> found that individuals with advanced fibrosis

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

(FIB-4  $\geq$  2.67) had a significantly higher risk of cardiovascular disease (HR = 1.60, 95% CI: 1.27-2.01) compared to those with inconclusive fibrosis (HR = 1.15, 95% CI: 1.01-1.31). Chun et al. <sup>59</sup> found a significant difference in the cumulative incidence of CVD among groups stratified by FIB-4. The severity of liver fibrosis was found to independently predict the occurrence of CVD in patients with T2DM. Additionally, the study revealed that the utilization of statins may serve as a protective factor (HR = 0.603) among individuals with T2DM, thereby mitigating the likelihood of developing CVD <sup>59</sup>. FIB-4 may have utility in the identification of individuals at elevated risk of CVD within the population of patients diagnosed with NAFLD. Conversely, the use of APRI for this purpose is not advised <sup>60</sup>. Our findings indicate that FIB-4 may be more effective than ALBI in assessing liver function in patients undergoing atorvastatin therapy. This is primarily due to the ability of FIB-4 to accurately monitor patients with severe liver damage, which was notably reduced in those receiving atorvastatin treatment. Prior research has indicated that statins may impact the levels of AST and ALT in NAFLD patients, as well as suggested that FIB-4 as a non-invasive test has an ability to predict hepatic fibrosis <sup>61</sup>. More importantly, our study revealed that both Atorvastatin and Rosuvastatin exhibited a dose-dependent reduction in FIB-4 levels among patients with CVD. A notable increase in the number of patients with FIB-4 grade < 1.45 and a decrease in those with FIB-4 grade > 3.25 were observed, particularly atorvastatin administration. Simon and colleagues 62 found that the use of statins was linked to a decrease in incident cirrhosis in a dose-dependent manner. Mohanty et al. 63 discovered that statin

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

use in patients with HCV is correlated with a reduction of over 40% in the risk of cirrhosis. The prevalence of cirrhosis was found to be 8% lower in the group receiving statin treatment compared to the statins-free group <sup>64</sup>. Furthermore, the use of statins was correlated with a reduced advancement of liver fibrosis and occurrence of hepatocellular carcinoma in a substantial population of Veterans with HCV infection <sup>64</sup>. The collective findings of these studies <sup>62-64</sup> and our own research indicate that statins exhibit the most pronounced antifibrotic effects. CBCIIs is an important predictor of chronic non-infectious inflammatory response, which is associated with the development of various metabolic system disorders such as fibrosis, hypertension, hyperlipidemia, and hyperglycemia 65-67. SIRI and SII are the two important inflammation indicators based on peripheral blood cell count <sup>32, 68</sup>. Prospective investigations have identified a correlation between elevated levels of white blood cells and their subtypes, such as neutrophils, monocytes, and lymphocytes, with an augmented susceptibility to coronary heart disease and stroke. Neutrophils are capable of releasing a plethora of inflammatory mediators, chemokines, and oxygen free radicals, thereby instigating endothelial cell damage, consequent tissue ischemia, and a pivotal role in the inflammatory response of atherosclerosis <sup>32,68,69</sup>. The activation and differentiation of monocytes into lipid-laden macrophages is a critical step in the pathogenesis of atherosclerotic plaques <sup>32,68,69</sup>. Consequently, novel systemic inflammatory markers, such as the SII and SIRI, which are derived from neutrophil counts and other parameters, are likely to be correlated with unfavorable cardiovascular outcomes. In our study, contrasting outcomes were

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

observed between SIRI and SII in assessing the impact of statin use in CVD patients. Specifically, our findings demonstrated a decrease in SIRI levels and an increase in SII levels in patients with CVD following statin therapy. Li et al. <sup>70</sup> demonstrated that SIRI is a strong predictor of all-cause mortality in CAD patients with low residual inflammatory risk. Numerous studies have indicated that the SII may serve as a potential biomarker for the development of CVD, with elevated levels of SII being linked to an increased risk of CVD 71-73. SII and SIRI have been linked to cardiovascular disease, yet the impact of statin therapy on these indices remains inconclusive. Following statin therapy, SII levels exhibited a significant increase, whereas SIRI levels showed a significant decrease. Consequently, the influence of statin therapy on the systemic inflammatory response in CVD patients remains uncertain and warrants further validation in a larger cohort. Utilizing initial data, our study determined that the utilization of statins resulted in a significant decrease in TC and LDL-C levels. Additionally, we conducted a thorough examination of the impact of statin use on atherogenic indices among individuals diagnosed with CVD. Higher values of novel atherogenic indices, including AIP, CRI-I, CRI-II, and LCI, were found to be significantly associated with an increased risk of coronary artery disease (CAD) when compared to lower values 35. Many investigations indicate that the AIP serves as a novel marker in the contemporary landscape of CVD, with elevated AIP emerging as an independent prognostic factor in patients with CAD 74-77. AI was independently associated with all-cause and CVD mortality among patients undergoing peritoneal dialysis <sup>37</sup>. Following adjustments for

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

potential confounders, the highest of AI value exhibited a notably increased hazard ratio for both all-cause mortality and CVD mortality when compared to the lowest AI value <sup>37</sup>. Hence, the majority of atherogenicity indicators hold significant implications for the diagnosis and prognosis of CVD risk events. Currently, there is a lack of relevant literature examining the relationship between statin use and atherogenicity indicators. Our research indicates that the use of statins has a significant impact on reducing levels of AI, CRI-I, CRI-II, and LCI. These findings suggest that statins may have a positive effect on liver fibrosis by improving lipid metabolism. Additionally, atherogenic indices such as AI, CRI-I, CRI-II, and LCI could serve as valuable markers for assessing liver fibrosis in patients undergoing statin therapy for CVD. It is important to acknowledge that our study has several limitations. Firstly, the recruitment of patients was limited to a single center, and the sample size was moderate. Secondly, there is a dearth of information pertaining to the duration of hyperlipidemia, hypertension, and diabetes. Consequently, when assessing the impact of diabetes and its complications, it is not possible to disregard the potential influence of unmeasured confounding factors. Thirdly, the measurement of HbA1c may be susceptible to interference from hemoglobin variants, hereditary hemoglobinopathies, thalassemia, and iron-deficiency anemia. However, HbA1c serves as a reliable indicator of prolonged blood glucose regulation and exhibits reduced inter-individual variability in contrast to impaired glucose tolerance and fasting plasma glucose. Moreover, it is crucial to acknowledge that our analysis solely encompasses a single measurement of HbA1c, thereby rendering the alterations in glycemic control

parameters indeterminate. Furthermore, this investigation solely encompasses inpatient data, precluding the assessment of long-term follow-up. Consequently, it is advisable to employ more sophisticated methodologies, such as cohort studies, to further investigate this matter.

### **CONCLUSION**

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

Our study indicates that CVD patients who also have HBV infection may experience a reduction in MACEs when treated with statins. DM with an HBA1c level of  $\geq 6$  is identified as risk factor for the development of CHD, MI, AP, and hypertension. The implementation of statins has demonstrated the potential to reduce the incidence of CHD and AP in individuals with CVD. The analysis of stratification, taking into account the presence of DM, has demonstrated a significantly increased vulnerability to MI, AMI, and HF among individuals with HBV infection combined with CVD. Furthermore, our findings reveal that long-term glycemic control should be prioritized in this patient population. Our findings also indicate that FIB-4 could serve as a potential indicator for assessing liver function in individuals undergoing treatment with statins. Statin therapy resulted in reduction in TC and LDL-C levels, as well as improvement of atherogenicity markers such as AI, CRI-I, CRI-II, and LCI. The results of our study indicate that statins may potentially ameliorate liver fibrosis through enhancement of lipid metabolism. Furthermore, atherogenic indices including AI, CRI-I, CRI-II, and LCI may serve as useful indicators for evaluating liver fibrosis in individuals receiving statin treatment for CVD. The observed improvements in hepatic function, atherosclerotic burden, and systemic inflammation associated with

statin therapy may contribute to the favorable outcomes among individuals with CVD. 610 611 612 **Sources of Funding** This work received financial support from the Natural Science Foundation of Shaanxi 613 Province, China (Grant No. 2022SF-243). 614 **Disclosures** 615 Prof. Wang received grants from the Natural Science Foundation of Shaanxi Province, 616 China. The authors declare that they have no competing interests. 617 **Supporting information** 618 Table S1-Table S14. 619

# REFERENCES

620

- 621 1. Global, regional, and national age-sex-specific mortality for 282 causes of
- death in 195 countries and territories, 1980-2017: A systematic analysis for the
- global burden of disease study 2017. Lancet (London, England).
- 624 2018;392:1736-1788. doi: 10.1016/S0140-6736 (18) 32203-7.
- 625 2. Stone PH, Libby P, Boden WE. Fundamental pathobiology of coronary
- atherosclerosis and clinical implications for chronic ischemic heart disease
- management-the plaque hypothesis: A narrative review. JAMA cardiology.
- 628 2023;8:192-201. doi: 10.1001/jamacardio.2022.3926.
- 629 3. Kamstrup PR. Lipoprotein(a) and cardiovascular disease. *Clinical chemistry*.
- 630 2021;67:154-166. doi: 10.1093/clinchem/hvaa247.
- 631 4. Ference BA, Graham I, Tokgozoglu L, Catapano AL. Impact of lipids on
- cardiovascular health: Jacc health promotion series. *Journal of the American*
- 633 College of Cardiology. 2018;72:1141-1156. doi: 10.1016/j.jacc.2018.06.046.
- 5. Vujkovic M, Keaton JM, Lynch JA, Assimes TL, Chang KM, Cho K, Lee JS,
- Gaziano JM, Phillips LS, Damrauer SM, DuVall SL, Gao L, Kaestner KH,
- Susztak K. Discovery of 318 new risk loci for type 2 diabetes and related
- vascular outcomes among 1.4 million participants in a multi-ancestry
- meta-analysis. *Nature genetics*. 2020;52:680-691. doi:
- 639 10.1038/s41588-020-0637-y.
- 640 6. Clarke R, Von Ende A, Hill M, Hopewell JC, Hughes AD, Mayr M, Pechlaner
- R, Schmidt LE, Theofilatos K, Watkins H, Watkins H, Yin X. Apolipoprotein

- proteomics for residual lipid-related risk in coronary heart disease. Circulation 642
- research. 2023;132:452-464. doi: 10.1161/CIRCRESAHA.122.321690. 643
- 7. Huang Y, Ren Y, Yang H, Ding Y, Liu Y, Yang Y, Mao A, Yang T, Wang Y, 644
- Xiao F, He O, Zhang Y. Using a machine learning-based risk prediction model 645
- to analyze the coronary artery calcification score and predict coronary heart 646
- and risk assessment. Computers in biology and medicine. 647
- 2022;151:106297. doi: 10.1016/j.compbiomed.2022.106297. 648
- Grandhi GR, Mirbolouk M, Dardari ZA, Al-Mallah MH, Rumberger JA, Shaw 8. 649
- 650 LJ, Blankstein R, Miedema MD, Berman DS, Budoff MJ, Krumholz HM,
- Blaha MJ, Nasir K. Interplay of coronary artery calcium and risk factors for 651
- predicting cvd/chd mortality: The cac consortium. JACC. Cardiovascular 652
- 653 imaging. 2020;13:1175-1186. doi: 10.1016/j.jcmg.2019.08.024.
- 9. Brown A, Reynolds LR, Bruemmer D. Intensive glycemic control and 654
- cardiovascular disease: update. Nature reviews. Cardiology. 655 An
- 2010;7:369-375. doi: 10.1038/nrcardio.2010.35. 656
- Nauta ST, Deckers JW, Akkerhuis KM, van Domburg RT. Short- and 10. 657
- long-term mortality after myocardial infarction in patients with and without 658
- diabetes: Changes from 1985 to 2008. Diabetes care. 2012;35:2043-2047. doi: 659
- 10.2337/dc11-2462 660
- Zhang YY, Hu KQ. Rethinking the pathogenesis of hepatitis b virus (hbv) 11. 661
- infection. Journal of medical virology. 2015;87:1989-1999. doi: 662
- 10.1002/jmv.24270. 663

perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 664 12. Cacoub P, Asselah T. Hepatitis b virus infection and extra-hepatic
- 665 manifestations: A systemic disease. *The American journal of gastroenterology*.
- 2022;117:253-263. doi: 10.14309/ajg.000000000001575.
- 667 13. Hamilton EM, Yang L, Avery D. Chronic hepatitis b virus infection and risk of
- stroke types: A prospective cohort study of 500 000 chinese adults. *Stroke*.
- 2023;54:3046-3053. doi: 10.1161/STROKEAHA.123.043327.
- 670 14. Kuo CS, Chen YT, Hsu CY, Chang CC, Chou RH, Li SY, Kuo SC, Huang PH,
- Chen JW, Lin SJ. The impact of chronic hepatitis b infection on major adverse
- cardiovascular events and all-cause mortality in patients with diabetes: A
- nationwide population-based study from taiwan. *BMJ open*. 2017;7:e016179.
- doi: 10.1136/bmjopen-2017-016179.
- 675 15. Ke ZP, Gong M, Zhao G, Geng Y, Cheng K. Association between hbv
- infection and the prevalence of coronary artery disease in the us population.
- 677 Computational and mathematical methods in medicine. 2022;2022:5062798.
- doi: 10.1155/2022/5062798.
- 679 16. Kumar A, Shariff M, Doshi R. Association between past hepatitis b infection
- and ischemic heart disease: An analysis from the 2007-2016 nhanes data. *The*
- American journal of the medical sciences. 2020;360:372-377. doi:
- 682 10.1016/j.amjms.2020.05.034.
- Ranković I, Milivojević V, Pavlović Marković A, Bezmarević M. Interplay
- between chronic hepatitis b and atherosclerosis: Innovative perspectives and
- theories. World journal of gastroenterology. 2022;28:497-499. doi:

10.3748/wjg.v28.i4.497.

686

- 687 18. Wu VC, Chen TH, Wu M, Cheng CW, Chen SW, Chang CW, Chen CC, Chang
- SH, Hung KC, Chern MS, Lin FC, Chu PH, Wu CS. Comparison of
- cardiovascular outcomes and all-cause mortality in patients with chronic
- hepatitis b and c: A 13-year nationwide population-based study in asia.
- 691 Atherosclerosis. 2018;269:178-184. doi:
- 692 10.1016/j.atherosclerosis.2018.01.007.
- 693 19. Kim D, Adejumo AC, Yoo ER, Igbal U, Li AA, Pham EA, Cholankeril G,
- Glenn JS, Ahmed A. Trends in mortality from extrahepatic complications in
- patients with chronic liver disease, from 2007 through 2017. Gastroenterology.
- 696 2019;157:1055-1066.e1011. doi: 10.1053/j.gastro.2019.06.026.
- 697 20. Liu XY, Zhou Y. Influence of hepatitis b virus on the prevalence of diabetes
- complications in patients with type 2 diabetes. Journal of diabetes
- *investigation*. 2023;14:429-434. doi: 10.1111/jdi.13954.
- 700 21. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn
- EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED,
- Miedema MD, Muñoz D, Smith SC, Jr., Virani SS, Williams KA, Sr., Yeboah J,
- Ziaeian B. 2019 acc/aha guideline on the primary prevention of cardiovascular
- disease: A report of the american college of cardiology/american heart
- association task force on clinical practice guidelines. Circulation.
- 706 2019;140:e596-e646. doi: 10.1161/CIR.0000000000000678.
- Lu Y, Zhang H, Lu J, Ding Q, Li X, Wang X, Sun D, Tan L, Mu L, Liu J, Feng

- F, Yang H, Zhao H, Schulz WL, Krumholz HM, Pan X, Li J. Prevalence of 708
- dyslipidemia and availability of lipid-lowering medications among primary 709
- 710 health care settings in china. JAMA network open. 2021;4:e2127573. doi:
- 10.1001/jamanetworkopen.2021.27573. 711
- 712 23. Sharpton SR, Loomba R. Emerging role of statin therapy in the prevention and
- management of cirrhosis, portal hypertension, and hcc. *Hepatology (Baltimore,* 713
- Md.). 2023;78:1896-1906. doi: 10.1097/HEP.000000000000278. 714
- Cho Y, Rhee H, Kim YE, Lee M, Lee BW, Kang ES, Cha BS, Choi JY, Lee 715 24.
- 716 YH. Ezetimibe combination therapy with statin for non-alcoholic fatty liver
- disease: An open-label randomized controlled trial (essential study). BMC 717
- medicine. 2022;20:93. doi: 10.1186/s12916-022-02288-2. 718
- 719 25. Shaffer LR, Mahmud N. Statins in cirrhosis: Hope or hype? *Journal of clinical*
- experimental hepatology. 2023;13:1032-1046. 720 and doi:
- 10.1016/j.jceh.2023.05.002. 721
- Dongiovanni P, Petta S, Mannisto V, Mancina RM, Pipitone R, Karja V, 722 26.
- Maggioni M, Kakela P, Wiklund O, Mozzi E, Grimaudo S, Kaminska D, 723
- Rametta R, Craxi A, Fargion S, Nobili V, Romeo S, Pihlajamaki J, Valenti L. 724
- Statin use and non-alcoholic steatohepatitis in at risk individuals. Journal of 725
- hepatology. 2015;63:705-712. doi: 10.1016/j.jhep.2015.05.006. 726
- Tessier CM, Polyzos SA, Athyros VG, Mantzoros CS. Long-term statin 27. 727
- treatment for hepatic fibrosis in patients with nonalcoholic fatty liver disease: 728
- Is it time to give the emperor a statin robe? Metabolism: clinical and 729

- experimental. 2021;121:154796. doi: 10.1016/j.metabol.2021.154796. 730
- 28. Boutari C, Pappas PD, Anastasilakis D, Mantzoros CS. Statins' efficacy in 731
- 732 non-alcoholic fatty liver disease: A systematic review and meta-analysis.
- Clinical nutrition (Edinburgh, Scotland). 2022;41:2195-2206. 733 doi:
- 10.1016/j.clnu.2022.08.001. 734
- Navarro P, Gutiérrez-Ramírez L, Arias Á, Lucendo AJ, Tejera-Muñoz A. 29. 735
- Systematic review and meta-analysis: Prevalence of non-alcoholic fatty liver 736
- disease and liver fibrosis in patients with inflammatory bowel disease. 737
- 738 Nutrients. 2023;15:4507. doi: 10.3390/nu15214507.
- 30. Martínez-Domínguez SJ, García-Mateo S, Laredo V, Gargallo-Puyuelo CJ, 739
- Gallego Llera B, López de la Cruz J, Gomollón F. Liver fibrosis in 740
- 741 non-alcoholic fatty liver disease and progression to hepatocellular carcinoma
- in patients with inflammatory bowel disease: A systematic review. Cancers. 742
- 2023;15:3367. doi: 10.3390/cancers15133367. 743
- Tian YB, Niu H, Xu F, Shang-Guan PW, Song WW. Albi score combined with 744 31.
- fib-4 index to predict post-hepatectomy liver failure in patients with 745
- hepatocellular carcinoma. Scientific 2024;14:8034. doi: 746 reports.
- 10.1038/s41598-024-58205-5. 747
- Li J, He D, Yu J, Chen S, Wu Q, Cheng Z, Wei Q, Xu Y, Zhu Y, Wu S. 748 32.
- Dynamic status of sii and siri alters the risk of cardiovascular diseases: 749
- Evidence from kailuan cohort study. Journal of inflammation research. 750
- 2022;15:5945-5957. doi: 10.2147/JIR.S378309. 751

752 33. Xiu J, Lin X, Chen Q, Yu P, Lu J, Yang Y, Chen W, Bao K, Wang J, Zhu J,

Zhang X, Pan Y, Tu J, Chen K, Chen L. The aggregate index of systemic

inflammation (aisi): A novel predictor for hypertension. Frontiers in

- cardiovascular medicine. 2023;10:1163900. doi: 10.3389/fcvm.2023.1163900.
- 756 34. Gaggini M, Gorini F, Vassalle C. Lipids in atherosclerosis: Pathophysiology
- and the role of calculated lipid indices in assessing cardiovascular risk in
- patients with hyperlipidemia. *International journal of molecular sciences*.
- 759 2022;24:75. doi: 10.3390/ijms24010075.

755

- 760 35. Mahdavi-Roshan M, Mozafarihashjin M, Shoaibinobarian N, Ghorbani Z,
- Salari A, Savarrakhsh A, Hekmatdoost A. Evaluating the use of novel
- atherogenicity indices and insulin resistance surrogate markers in predicting
- the risk of coronary artery disease: A case-control investigation with
- comparison to traditional biomarkers. Lipids in health and disease.
- 765 2022;21:126. doi: 10.1186/s12944-022-01732-9.
- 766 36. Vargas HO, Nunes SO, Barbosa DS, Vargas MM, Cestari A, Dodd S,
- Venugopal K, Maes M, Berk M. Castelli risk indexes 1 and 2 are higher in
- major depression but other characteristics of the metabolic syndrome are not
- specific to mood disorders. Life sciences. 2014;102:65-71. doi:
- 770 10.1016/j.lfs.2014.02.033.
- 771 37. Deng J, Tang X, Tang R, Chen J, Guo H, Zhou Q, Zhan X, Long H, Peng F,
- Wang X, Wen Y, Feng X, Su N, Tian N, Wu X, Xu Q. Atherogenic index
- predicts all-cause and cardiovascular mortality in incident peritoneal dialysis

perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license.

- patients. Atherosclerosis. 2023;387:117389. doi:
- 775 10.1016/j.atherosclerosis.2023.117389.
- 776 38. Oesterle A, Laufs U, Liao JK. Pleiotropic effects of statins on the
- cardiovascular system. Circulation research. 2017;120:229-243. doi
- 778 10.1161/CIRCRESAHA.116.308537.
- 779 39. Tian T, Song C, Jiang L, Dai J, Lin Y, Xu X, Yu C, Ge Z, Ding Y, Wen Y, Liu
- 780 B, Shao Y, Shi P, Zhu C, Liu Y, Jing S, Wang Z, Hu Z, Li J. Hepatitis b virus
- infection and the risk of cancer among the chinese population. *International*
- 782 *journal of cancer*. 2020;147:3075-3084. doi: 10.1002/ijc.33130.
- 783 40. Motamed-Gorji N, Eghtesad S, Sharafkhah M, Masoudi S, Darvishian M,
- Eslami L, Gharavi A, Khoshnia M, Roshandel G, Shayanrad A, Hariri S,
- Merat S, Poustchi H, Malekzadeh R. All-cause and cause-specific mortality in
- middle-aged individuals with positive hbsag: Findings from a prospective
- 787 cohort study. Archives of Iranian medicine. 2022;25:139-147. doi:
- 788 10.34172/aim.2022.24.
- 789 41. Cheng YM, Hsieh TH, Wang CC, Kao JH. Impact of hbv infection on clinical
- outcomes in patients with metabolic dysfunction-associated fatty liver disease.
- 791 JHEP reports: innovation in hepatology. 2023;5:100836. doi:
- 792 10.1016/j.jhepr.2023.100836.
- 793 42. Khawaja T, Linge J, Leinhard OD, Al-Kindi SG, Rajagopalan S, Khera A, de
- Lemos JA, Joshi P, Neeland IJ. Coronary artery calcium, hepatic steatosis, and
- atherosclerotic cardiovascular disease risk in patients with type 2 diabetes

perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

mellitus: Results from the dallas heart study. Progress in cardiovascular 796 diseases. 2023;78:67-73. doi: 10.1016/j.pcad.2023.03.002. Epub 2023 Mar 797 798 15. Bauer T, Möllmann H, Weidinger F, Zeymer U, Seabra-Gomes R, Eberli F, 43. 799 Serruys P, Vahanian A, Silber S, Wijns W, Hochadel M, Nef HM, Hamm CW, 800 Marco J, Gitt AK. Impact of diabetes mellitus status on coronary 801 pathoanatomy and interventional treatment: Insights from the euro heart 802 survey pci registry. Catheterization and cardiovascular interventions: official 803 804 journal of the Society for Cardiac Angiography & Interventions. 2011;78:702-709. doi: 10.1002/ccd.22939. 805 Rana JS, Dunning A, Achenbach S, Al-Mallah M, Budoff MJ, Cademartiri F, 44. 806 807 Callister TQ, Chang HJ, Cheng VY, Chinnaiyan K, Chow BJ, Cury R, Delago A, Feuchtner G, Hadamitzky M, Hausleiter J, Kaufmann P, Karlsberg RP, Kim 808 YJ, Leipsic J, Labounty TM, Lin FY, Maffei E, Raff G, Villines TC, Shaw LJ, 809 810 Berman DS, Min JK. Differences in prevalence, extent, severity, and prognosis of coronary artery disease among patients with and without diabetes 811 undergoing coronary computed tomography angiography: Results from 10,110 812 individuals from the confirm (coronary ct angiography evaluation for clinical 813 814 outcomes): An international multicenter registry. Diabetes care. 2012;35:1787-1794. doi: 10.2337/dc11-2403. 815 816 45. Scicali R, Giral P, Gallo A, Di Pino A, Rabuazzo AM, Purrello F, Cluzel P, Redheuil A, Bruckert E, Rosenbaum D. Hba1c increase is associated with 817

perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license.

higher coronary and peripheral atherosclerotic burden in non diabetic patients. 818 Atherosclerosis. 2016;255:102-108. doi: 819 10.1016/j.atherosclerosis.2016.11.003. 820 Maiorino MI, Longo M, Scappaticcio L, Bellastella G, Chiodini P, Esposito K, 821 46. Giugliano D. Improvement of glycemic control and reduction of major 822 cardiovascular events in 18 cardiovascular outcome trials: An updated 823 meta-regression. diabetology. Cardiovascular 2021;20:210. doi: 824 10.1186/s12933-021-01401-8. 825 Fralick M, Colacci M, Odutayo A, Siemieniuk R, Glynn RJ. Lowering of 826 47. hemoglobin a1c and risk of cardiovascular outcomes and all-cause mortality, a 827 meta-regression analysis. Journal of diabetes and its complications. 828 829 2020;34:107704. doi: 10.1016/j.jdiacomp.2020.107704. 48. Wan EYF, Yu EYT, Mak IL, Youn HM, Chan KS, Chan EWY, Wong ICK, 830 Lam CLK. Diabetes with poor-control hba1c is cardiovascular disease 'risk 831 832 equivalent' for mortality: Uk biobank and hong kong population-based cohort study. BMJopen diabetes research & 2023;11. doi: 833 care. 10.1136/bmjdrc-2022-003075. 834 49. Vell MS, Loomba R, Krishnan A, Wangensteen KJ, Trebicka J, Creasy KT, 835 Trautwein C, Scorletti E, Seeling KS, Hehl L, Rendel MD, Zandvakili I, Li T, 836 Chen J, Vujkovic M, Algahtani S, Rader DJ, Schneider KM, Schneider CV. 837 Association of statin use with risk of liver disease, hepatocellular carcinoma, 838 and liver-related mortality. JAMA network open. 2023;6:e2320222. doi: 839

10.1001/jamanetworkopen.2023.20222.

- 841 50. Yun B, Ahn SH, Yoon JH, Kim BK. Statin use and risk of progression to liver
- cirrhosis in chronic hepatitis b independent of conventional risk factors: A
- nationwide study. *Hepatology communications*. 2022;6:2455-2464. doi:
- 844 10.1002/hep4.2022.

- Hsiang JC, Wong GL, Tse YK, Wong VW, Yip TC, Chan HL. Statin and the
- risk of hepatocellular carcinoma and death in a hospital-based hepatitis
- b-infected population: A propensity score landmark analysis. *Journal of*
- hepatology. 2015;63:1190-1197. doi: 10.1016/j.jhep.2015.07.009.
- 849 52. Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Statins are asso
- eciated with a reduced risk of hepatocellular cancer: A systematic review
- and meta-analysis. *Gastroenterology*. 2013;144:323-332. doi: 10.1053/j.gas
- 852 tro.2012.10.005.
- 853 53. Cheung KS, Mak LY, Lam LK, Fung J, Liu F, Seto WK, Yuen MF. Statins
- associate with better clinical outcomes in chronic hepatitis b patients with
- hbsag seroclearance. *Hepatology international*. 2021;15:881-891. doi:
- 856 10.1007/s12072-021-10197-4.
- van de Klundert M, Ringelhan M, Protzer U. Statins suppress hepatitis b virus
- replication and reduce hepatoma cell viability by interfering with rho-gtpases.
- *Journal of hepatology.* 2018;68:S782. doi: 10.1016/S0168-8278(18)31833-6
- 860 55. Guan L, Li L, Zou Y, Zhong J, Qiu L. Association between fib-4, all-cause
- mortality, cardiovascular mortality, and cardiovascular disease risk among

diabetic individuals: Nhanes 1999-2008. Frontiers in cardiovascular medicine.

863 2023;10:1172178. doi: 10.3389/fcvm.2023.1172178.

- 864 56. Seo YG, Polyzos SA, Park KH, Mantzoros CS. Fibrosis-4 index predicts
- long-term all-cause, cardiovascular and liver-related mortality in the adult
- korean population. Clinical gastroenterology and hepatology: the official
- 867 clinical practice journal of the American Gastroenterological Association.
- 868 2023;21:3322-3335. doi: 10.1016/j.cgh.2023.04.026.
- 869 57. Roca-Fernandez A, Banerjee R, Thomaides-Brears H, Telford A, Sanyal A,
- Neubauer S, Nichols TE, Raman B, McCracken C, Petersen SE, Ntusi NA,
- Cuthbertson DJ, Lai M, Dennis A, Banerjee A. Liver disease is a significant
- 872 risk factor for cardiovascular outcomes a uk biobank study. *Journal of*
- hepatology. 2023;79:1085-1095. doi: 10.1016/j.jhep.2023.05.046.
- 58. Schonmann Y, Yeshua H, Bentov I, Zelber-Sagi S. Liver fibrosis marker is an
- independent predictor of cardiovascular morbidity and mortality in the general
- population. Digestive and liver disease: official journal of the Italian Society
- of Gastroenterology and the Italian Association for the Study of the Liver.
- 878 2021;53:79-85. doi: 10.1016/j.dld.2020.10.014. Epub 2020 Nov 2.
- 879 59. Chun HS, Lee JS, Kim BK, Lee HW, Lee YH, Kim YD, Kim SU, Park JY,
- Kim DY, Ahn SH. Association between the severity of liver fibrosis and
- cardiovascular outcomes in patients with type 2 diabetes. Journal of
- gastroenterology and hepatology. 2021;36:1703-1713. doi:
- 883 10.1111/jgh.15387.

- 884 60. Yi M, Peng W, Teng F, Kong Q, Chen Z. The role of noninvasive scoring
- systems for predicting cardiovascular disease risk in patients with
- nonalcoholic fatty liver disease: A systematic review and meta-analysis.
- European journal of gastroenterology & hepatology. 2022;34:1277-1284. doi:
- 888 10.1097/MEG.000000000002462.
- 889 61. Al-Karaghouli M, Fuentes S, Davyduke T, Ma M, Abraldes JG. Impact of
- statin treatment on non-invasive tests based predictions of fibrosis in a referral
- pathway for nafld. BMJ open gastroenterology. 2022;9:e000798. doi:
- 892 10.1136/bmjgast-2021-000798.
- 893 62. Simon TG, Bonilla H, Yan P, Chung RT, Butt AA. Atorvastatin and fluvastatin
- are associated with dose-dependent reductions in cirrhosis and hepatocellular
- carcinoma, among patients with hepatitis c virus: Results from erchives.
- 896 *Hepatology (Baltimore, Md.).* 2016;64:47-57. doi: 10.1002/hep.28506.
- 897 63. Mohanty A, Tate JP, Garcia-Tsao G. Statins are associated with a decreased
- risk of decompensation and death in veterans with hepatitis c-related
- 899 compensated cirrhosis. Gastroenterology. 2016;150:430-440.e431.doi:
- 900 10.1053/j.gastro.2015.10.007.
- 901 64. Butt AA, Yan P, Bonilla H, Abou-Samra AB, Shaikh OS, Simon TG, Chung
- 902 RT, Rogal SS. Effect of addition of statins to antiviral therapy in hepatitis c
- 903 virus-infected persons: Results from erchives. *Hepatology (Baltimore, Md.)*.
- 904 2015;62:365-374. doi: 10.1002/hep.27835.
- 905 65. Yousaf H, Khan MIU, Ali I, Munir MU, Lee KY. Emerging role of

macrophages in non-infectious diseases: An update. Biomedicine & 906 pharmacotherapy = Biomedecine & pharmacotherapie. 2023;161:114426.doi: 907 10.1016/j.biopha.2023.114426. 908 Cho S, Ying F, Sweeney G. Sterile inflammation and the nlrp3 inflammasome 909 66. in cardiometabolic disease. Biomedical journal. 2023;46:100624. doi: 910 10.1016/j.bj.2023.100624. 911 Zinellu A, Paliogiannis P. Blood cell count derived inflammation indexes in 912 67. patients with idiopathic pulmonary fibrosis. Lung. 2020;198:821-827. doi: 913 914 10.1007/s00408-020-00386-7. 68. Kong F, Huang J, Xu C, Huang T, Wen G, Cheng W. System inflammation 915 response index: A novel inflammatory indicator to predict all-cause and 916 917 cardiovascular disease mortality in the obese population. Diabetology & metabolic syndrome. 2023;15:195. doi: 10.1186/s13098-023-01178-8. 918 Wang P, Guo X, Zhou Y, Li Z, Yu S, Sun Y, Hua Y. Monocyte-to-high-density 69. 919 920 lipoprotein ratio and systemic inflammation response index are associated with the risk of metabolic disorders and cardiovascular diseases in general 921 population. Frontiers in endocrinology. 2022;13:944991. 922 10.3389/fendo.2022.944991. 923 Li T, Wang P, Wang X, Liu Z, Zhang Z, Zhang Y, Wang Z, Feng Y, Wang Q, 924 70. Guo X, Tang X, Xu J, Song Y, Chen Y, Xu N, Yao Y, Liu R, Zhu P, Han Y, 925 Yuan J. Prognostic significance of inflammation in patients with coronary 926

artery disease at low residual inflammatory risk. iScience. 2023;26:108060.

doi: 10.1016/j.isci.2023.108060.

- 929 71. Ye Z, Hu T, Wang J, Xiao R, Liao X, Liu M, Sun Z. Systemic
- immune-inflammation index as a potential biomarker of cardiovascular
- diseases: A systematic review and meta-analysis. Frontiers in cardiovascular
- 932 *medicine*. 2022;9:933913. doi: 10.3389/fcvm.2022.933913.
- 933 72. Ma J, Li K. Systemic immune-inflammation index is associated with coronary
- heart disease: A cross-sectional study of nhanes 2009-2018. Frontiers in
- 935 *cardiovascular medicine*. 2023;10:1199433. doi: 10.3389/fcvm.2023.1199433.
- 236 73. Zhao Z, Zhang X, Sun T, Huang X, Ma M, Yang S, Zhou Y. Prognostic value
- of systemic immune-inflammation index in cad patients: Systematic review
- and meta-analyses. European journal of clinical investigation.
- 939 2024;54:e14100. doi: 10.1111/eci.14100.
- 940 74. Rabiee Rad M, Ghasempour Dabaghi G, Darouei B, Amani-Beni R. The
- association of atherogenic index of plasma with cardiovascular outcomes in
- patients with coronary artery disease: a systematic review and meta-analysis.
- 943 *Cardiovascular diabetology*. 2024;23:119. doi: 10.1186/s12933-024-02198-y.
- 944 75. Min Q, Wu Z, Yao J, Wang S, Duan L, Liu S, Zhang M, Luo Y, Ye D, Huang Y,
- Chen L, Xu K, Zhou J. Association between atherogenic index of plasma
- control level and incident cardiovascular disease in middle-aged and elderly
- chinese individuals with abnormal glucose metabolism. Cardiovascular
- 948 *diabetology*. 2024;23:54. doi: 10.1186/s12933-024-02144-y.
- 949 76. Wang Y, Wang S, Sun S, Li F, Zhao W, Yang H, Wu X. The predictive value of

950

951

952

953

954

955

956

957

958

959

960

961

962

963

964

965

966

967

968

969

970


971

atherogenic index of plasma for cardiovascular outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention with ldl-c below 1.8mmol/l. Cardiovascular diabetology. 2023;22:150. doi: 10.1186/s12933-023-01888-3. 77. Fernández-Macías JC, Ochoa-Martínez AC, Varela-Silva JA, Pérez-Maldonado IN. Atherogenic index of plasma: Novel predictive biomarker for cardiovascular illnesses. Archives of medical research. 2019;50:285-294. doi: 10.1016/j.arcmed.2019.08.009. Figure legends Figure 1 Flow diagram of cohort selection. Consequently, a final sample size of 496 participants was included in the study. The patients were categorized into two groups according to their surface antigen status: patients with coexisting CVD and HBV (n = 225) and patients with CVD alone (n = 271). CVD, cardiovascular disease; HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen. Figure 2 The impact of HBV infection, stratified by statins use, on multiple clinical outcomes among CVD patients. OR, odds ratio; CDH, coronary heart disease; MI, myocardial infarction; AP, angina pectoris; DM, diabetes mellitus; CCU, coronary care unit; AMI, acute myocardial infarction; UAP, unstable angina pectoris; HF, heart failure. Figure 3 The impact of HBV infection, stratified by DM, on multiple clinical outcomes among CVD patients. OR, odds ratio; CDH, coronary heart disease; MI,

myocardial infarction; AP, angina pectoris; DM, diabetes mellitus; CCU, coronary care unit; AMI, acute myocardial infarction; UAP, unstable angina pectoris; HF, heart failure.

Figure 4 The impact of DM, stratified by statins use, on multiple clinical outcomes among CVD patients. OR, odds ratio; CDH, coronary heart disease; MI, myocardial infarction; AP, angina pectoris; DM, diabetes mellitus; CCU, coronary care unit; AMI, acute myocardial infarction; UAP, unstable angina pectoris; HF, heart failure.

Figure 5 The impact of HbA1c (≥6% or < 6%), stratified by statins use, on multiple clinical outcomes among CVD patients. OR, odds ratio; CDH, coronary heart disease; MI, myocardial infarction; AP, angina pectoris; DM, diabetes mellitus; CCU, coronary care unit; AMI, acute myocardial infarction; UAP, unstable angina pectoris; HF, heart failure.



Characteristics	Total (N)	OR (95% CI)		P value
CDH	427	Defenses	!	0.001
no	39	Reference	<b>A</b> . I	
yes MI	388 427	0.27 (0.12 - 0.60)	<b>~</b> }	0.815
no	274	Reference	i	0.013
yes	153	1.08 (0.69 - 1.68)	ı <b>♦</b> →	
AP	153 427	(6.65)	ř	0.008
no	119	Reference	1	
yes	308	0.56 (0.36 - 0.86)	<b>∳</b> -I	
Hypertension (extreme risk)	427		<u>!</u>	0.436
no	<u> 25</u> 6	Reference	1	
yes	17 <u>1</u>	0.82 (0.53 - 1.27)	•	0.400
ĎМ	427	Defende	:	0.136
no	299	Reference	<u>.</u>	
yes CCU	128 427	0.68 (0.42 - 1.09)	<b>1</b>	0.611
	331	Reference	Ī	0.611
no Ves	96	1.17 (0.71 - 1.94)		
yes AMI	427	1.17 (0.71 - 1.94)		0.001
no	296	Reference	I	0.001
yes	131	2.24 ( 1.40 - 3.57)	¹ ⊦ <b>→</b> − →	
ÚĂP	427	2.21(1.10 0.01)	ı	0.953
no	86	Reference	!	0.000
	341	0.84 (0.52 - 1.36)	ı <b>♦</b> ⊸	
yes HF	427	,	:	0.304
no	351	Reference	•	
yes	76_	1.50 (0.91 - 2.50)	<b>† ◆</b> − →	
NYHA classification	427	D (	i	0.436
Class I	98	Reference	<u>م</u> ا	
≥ Class II	329	0.67 (0.42 - 1.06)	<b>'</b>	0.000
Killip classification	427 417	Deference	1	0.939
Class I ≥ Class II	417 10	Reference 2.05 (0.52 - 8.03)		_
Secondary clinical outcome	427	2.03 (0.32 - 6.03)	- <del></del>	0.17
no	74	Reference	!	0.17
yes	353	1.53 (0.88 - 2.66)	<del> </del>	
Primary clinical outcome	427	1.00 (0.00 2.00)	I ▼	0.624
no	59	Reference	,	0.02
yes	368	0.97 (0.56 - 1.69)	<b>⊦</b>	

Characteristics	Total (N)	OR (95% CI)	P value
CDH no	496 45	Reference	0.004
yes	451	0.32 (0.15 - 0.68)	<b>♦</b> !
MI (non-DM)	223	,	0.384
` no	164	Reference	
yes MI (DM)	59 273	0.76 (0.42 - 1.40)	0.002
no	154	Reference	0.002
yes	119	2.12 (1.30 - 3.45)	i <b>♦</b> →
ΆP	496	, , , , , , , , , , , , , , , , , , ,	ı 0.084
no	137 359	Reference	<u> </u>
yes Hypertension (extreme risk)	496	0.68 (0.45 - 1.03)	0.828
no	299	Reference	1
yes	197	0.94 (0.65 - 1.37)	<b>•</b>
ĆCU	496	Deference	0.497
no yes	396 100	Reference 1.20 (0.77 - 1.87)	
AMI (non-DM)	223	1.20 (0.77 - 1.07)	0.396
no	138	Reference	1
yes	85	0.79 (0.45 - 1.37)	4
AMI (DM)	273 200	Reference	< 0.001
no yes	73	5.37 (2.91 - 9.92)	! <b></b>
ÚÁP	496	0.07 (2.01 0.02)	0.412
no	99	Reference	j
yes	397	0.81 (0.51 - 1.27)	0.510
HF (non-DM) no	223 175	Reference	0.519
yes	48	0.81 (0.42 - 1.55)	<b>4</b> -
HF (DM)	273	,	0.005
no	227	Reference	1
yes NYHA classification	46 496	2.58 (1.32 - 5.04)	0.468
Class I	108	Reference	i 0.400
≥ Class II	388	0.83 (0.54 - 1.28)	<b>•</b>
Killip classification	496	,	9.243
Class I	485	Reference	
≥ Class II Secondary clinical outcome (non-DM)	11 223	2.25 (0.59 - 8.59)	0.981
no	37	Reference	1
yes	186	1.01 (0.49 - 2.09)	<b>∳</b> →
Secondary clinical outcome (DM)	273	, Defe	< 0.001
no yes	47 226	Reference 4.34 (2.06 - 9.15)	<sup>1</sup>
Primary clinical outcome	496	7.07 (2.00 - 3.13)	0.847
no	65	Reference	1
ves	431	0.91 (0.53 - 1.56)	<b>◆</b> •

Characteristics	Total (N)	OR (95% CI)		P value
CDH	494	<u> </u>	- '- 	< 0.001
no	44	Reference	İ	
yes	450	6.9 (3.2 - 14.9)	I	
MI	494	,	1	< 0.001
no	316	Reference	!	
yes	178	2.2 (1.5 - 3.2)	<b></b>	
AP (no statins use)	79	,	Ī	0.01
no	34	Reference	1	
yes	45	3.5 (1.3 - 9.3)	ŀ <b>◆</b> →	
AP (atorvastatin 20 mg)	225	,	!	0.063
no	51	Reference		
yes	174	1.8 (1.0 - 3.4)	i <b>♦</b> ⊣	
AP (rosuvastatin 10 mg)	190	,	1	0.669
` no	51	Reference	1	
yes	139	0.87 (0.46 - 1.65)	<b>•</b>	
Hypertension (extreme risk)	494	,	!	< 0.001
no	297	Reference	i	
yes	197	2.9 (2.0 - 4.2)	i 📥	
ĆĊŪ	494	,	1	0.554
no	394	Reference	I	
yes	100	1.2 (0.7 - 1.9)	•	
ÁMI	494	(311 113)	r 1	0.006
no	337	Reference	i	0.000
yes	157	0.57 (0.39 - 0.84)	<b>*</b>	
ÚAP	494	(1111)	Ĭ	0.059
no	99	Reference	!	0.000
yes	395	0.63 (0.39 - 0.99)	<b>4</b>	
HF	494	0.00 (0.00 0.00)	1	0.166
no	403	Reference	Î	01.00
yes	93	0.70 (0.45 - 1.11)	<b>4</b>	
NYHA classification	494	3 3 (31.13 11.11)	<u>1</u>	0.879
Class I	108	Reference	1	0.070
≥ Class II	386	1.1 (0.7 - 1.6)	•	
Killip classification	494	(5.7 1.0)	Ĭ	0.195
Class I	483	Reference	ı	5.100
≥ Class II	11	3.3 (0.7 - 15.7)	·!- •	
Secondary clinical outcome	494	0.0 (0.7 10.7)	i *	0.787
no	84	Reference		0.101
yes	410	0.91 (0.57 - 1.46)	•	
Primary clinical outcome	494	0.01 (0.01 1.70)	Ĭ	0.208
no	65	Reference	I	0.200
yes	429	0.68 (0.40 - 1.17)	<b>↓</b>	
<del>,</del> 50	120	3.00 (3.10 1.11)	0 5 10 15	

Characteristics CDH (no statins use) no yes CDH (atorvastatin 20 mg) no yes CDH (rosuvastatin 10 mg)	Total (N) 76 14 62 218 19	OR (95% CI)  Reference 34.4 (4.2 - 283.6)		< 0.001
no yes CDH (atorvastatin 20 mg) no yes	14 62 218		1	
CDH (atorvastatin 20 mg) no ves	218		I •	
CDH (atorvastatin 20 mg) no ves	218		<del>_</del>	
no ves	19	,		0.085
ves		Reference		
CDH (rosuvastatin 10 mg)	199	2.3 (0.9 - 5.9)	•	
	186	()	, , , , , , , , , , , , , , , , , , ,	1
no	8	Reference		•
yes	178	1.2 (0.3 - 5.1)	<b>.</b>	
MI	480	1.2 (0.0 0.1)	Ĭ	0.024
no	305	Reference	;	0.02 1
yes	175	1.6 (1.1 - 2.3)	<b>.</b>	
AP (no statins use)	76	1.0 (1.1 - 2.3)	Y	0.019
no	33	Reference	i	0.013
	43	3.1 (1.2 - 8.1)	·	
yes	218	3.1 (1.2 - 0.1)	<b>Y</b>	0.09
AP (atorvastatin 20 mg)		Reference	i	0.09
no	48			
yes	170	1.7 (0.9 - 3.3)	<b>Y</b>	0.004
AP (rosuvastatin 10 mg)	186	D = f =	i	0.004
no	50	Reference	À	
yes	136	0.37 (0.18 - 0.74)	<b>T</b>	. 0 004
Hypertension (extreme risk)	480	D (	i	< 0.001
no	288	Reference	k	
yes	192	2.7 (1.9 - 4.1)	•	
ČCU	480	_	i	0.341
no	381	Reference	i	
yes	99	1.3 (0.8 - 2.1)	•	
ÅΜΙ	480	,	ī	0.903
no	329	Reference	ı	
yes	151	0.96 (0.65 - 1.41)	<b>•</b>	
ÚAP	480	,	I	0.205
no	95	Reference	i	
yes	385	0.72 (0.45 - 1.15)	•	
ĤĔ	480	0.72 (0.10 1.10)	Ĭ	0.48
no	392	Reference	1	0.10
yes	88	0.82 (0.51 - 1.31)	•	
NYHA classification	480	0.02 (0.01 1.01)	Ĭ	0.408
Class I	105	Reference	1	0.400
≥ Class II	375	0.81 (0.52 - 1.26)	<b>_</b>	
	480	0.01 (0.32 - 1.20)	Ť	0.066
Killip classification		Reference	ı	0.000
Class I	469 11		<b>!</b>	
≥ Class II	11	6.9 (0.9 - 53.2)	i	0.000
Secondary clinical outcome	480	D-f	ı	0.222
no	82	Reference	1	
yes	398	0.71 (0.43 - 1.17)	₹	0.000
Primary clinical outcome	480	D (	ı	0.689
no	62	Reference	1	
yes	418	<u> 0.86 (0.50 - 1.49)</u>	•	

Table 1. Baseline characteristics of CVD with HBV and CVD alone participants.

Indices	CVD	HBV+CVD	t/χ <sup>2</sup>	P-value
N	225	271	0.333	
age (years, mean $\pm$ SD)	60.21±10.41	59.90±10.18		0.739
Gender			4.463	0.035
Female [n (%)]	66(29.3%)	104(38.4%)		
Male [n (%)]	159(70.7%)	167(61.6%)		
Hypertension [n (%)]			0.328	0.567
No	75(33.3%)	97(35.8%)		
Yes	150(66.7%)	174(64.2%)		
DM [n (%)]			9.679	0.002
No	84(37.3%)	139(51.3%)		
Yes	141(62.7%)	132(48.7%)		
Smoking history [n (%)]			0.656	0.418
No	145(64.4%)	184(67.9%)		
Yes	80(35.5%)	87(32.1%)		
Drinking history [n (%)]			0.562	0.453
No	188(83.6%)	233(86.0%)		
Yes	37(16.4%)	38(14.0%)		
Height (cm)	167.00±7.19	165.00±8.42	1.900	0.058
Weight (kg)	70.42±10.46	68.25±12.23	2.038	0.042
BMI ( $kg/m^2$ )	25.23±3.22	24.68±3.76	1.66	0.098
Inpatient days (day)	3.70±1.68	4.12±2.91	-1.910	0.057
Pre-hospital medication [n (%)]			69.551	0.000
No	2(0.9%)	77(28.4%)		
Yes	223(99.1%)	194(71.6%)		
Statin use [n (%)]			11.102	0.011
No	2(0.9%)	16(5.9%)		
rosuvastatin	88(39.1%)	118(43.5%)		
atorvastatin	134(56.9%)	136(50.2%)		
simvastatin	1(0.4%)	1(0.4%)		
Dosage (mg/day)	16.87±7.43	15.55±6.59	2.037	0.042
NYHA classification [n (%)]			0.761	0.383
I	45(20%)	63(23.2%)		
II-IV	180(80%)	208(76.8%)		
Kililip classification [n (%)]			1.485	0.223
I	222(98.7%)	263(97.0%)		
II-IV	3(1.3%)	8(3.0%)		
Adverse event				
AMI [n (%)]			14.504	0.000
No	173(76.9%)	165(60.9%)		
Yes	52(23.1%)	106(39.1%)		

UAP [n (%)]			0.431	0.512
No	42(18.7%)	57(21%)		
Yes	183(81.3%)	214(79%)		
HF [n (%)]			3.092	0.079
No	190(84.4%)	212(78.2%)		
Yes	35(15.6%)	59(21.8%)		
LDL-C (mmol/L)	2.01±0.82	2.05±0.90	-0.418	0.676
TG (mmol/L)	1.45±0.83	1.26±0.75	2.678	0.008
HDL-C (mmol/L)	0.97±0.24	0.96±0.24	0.518	0.605
ApoA (g/L)	1.13±0.18	1.10±0.19	1.879	0.061
ApoB (g/L)	0.69±0.23	0.68±0.22	0.453	0.651
ApoE (mmol/L)	33.22±14.79	32.40±13.63	0.641	0.522
Lp(a) (mg/L)	330.17±296.68	262.34±247.03	2.767	0.006
TC (mmol/L)	3.66±1.01	3.54±1.00	1.309	0.191
non-HDL-C (mmol/L)	2.68±0.94	2.58±0.94	1.094	0.275
CYS-C (mg/L)	0.93±0.18	0.98±0.35	-1.906	0.057
$LY \times 10^9/L$	1.51±0.58	1.55±0.58	-0.711	0.478
$MO (\times 10^9/L)$	0.45±0.20	0.43±0.22	1.205	0.229
NE (× $10^9$ /L)	4.72±1.76	4.42±1.95	1.794	0.073
PLT (× 10 <sup>9</sup> /L)	208.41 ± 59.35	190.94 ± 61.39	3.195	0.001
NHR	5.19±2.38	4.99±2.76	0.811	0.418
MHR	0.50±0.27	0.49±0.36	0.312	0.755
NLR	3.66±2.35	3.99±2.76	1.165	0.245
PLR	153.20±63.91	139.16±73.53	2.236	0.026
THR	1.63±1.22	1.46±1.20	1.542	0.124
BNP (pg/L)	477.90±928.33	839.05±2948.05	-1.761	0.079
HbA1c (%)	6.49±1.24	6.43±1.35	0.453	0.651
HBsAg (IU/mL)	0.00±0.00	$208.15 \pm 652.68$	-4.787	0.000
HbsAb (mIU/mL)	62.44±137.92	$3.99 \pm 20.19$	6.69	0.000
HBeAg (S/CO)	0.38±0.06	$26.58 \pm 179.70$	-2.153	0.032
HBeAb (S/CO)	2.41±2.86	$7.84 \pm 1.07$	1.008	0.314
HbcAb (S/CO)	2.41±2.86	$7.84 \pm 1.07$	-28.16	0.000
ALT (U/L)	29.91±19.45	$31.33 \pm 19.74$	-0.925	0.355
AST (U/L)	$37.69 \pm 66.37$	41.57 ± 67.14	-0.642	0.521
AST/ALT	$1.21 \pm 0.96$	$1.26 \pm 1.03$	-0.548	0.584
TBil (μmol/L)	$14.24 \pm 6.83$	$14.97 \pm 6.76$	-1.164	0.245
ALP (U/L)	$78.85 \pm 2.94$	$84.83 \pm 92.29$	-0.922	0.357

AMI, acute myocardial infarction; UAP, unstable angina pectoris; HF, heart failure; HbA1c, hemoglobin A1c; BNP, brain natriuretic peptide; ALT, glutamic-pyruvic transaminase; AST, glutamic oxalacetic transaminase; TBil, total bilirubin; ALP, alkaline phosphatase; HBsAg, hepatitis B surface antigen; HbsAb, hepatitis B surface antibody; HBeAg, hepatitis E surface antigen; HbeAb, hepatitis E surface antibody; HbcAb, hepatitis B core antibody; TG, triglycerides; Lp(a), lipoprotein(a); PLR, platelet-to-lymphocyte ratio, PLT, platelet count; MO, Monocyte count; NE, neutrophil count; CVD, cardiovascular disease; HBV, hepatitis B virus; DM, diabetes mellitus; THR, thyroid hormone receptor; NHR, nuclear hormone receptor; MHR, monocyte-to-high-density lipoprotein-cholesterol ratio; LDL-C, low-density high-density lipoprotein cholesterol; HDL-C, lipoproteincholesterol; apolipoprotein A; ApoB, apolipoprotein B; ApoE, apolipoprotein E; TC, total cholesterol; no-HDL-C, non-HDL cholesterol; CYS-C, cystatin C.

Table 2. Relationship between statin use and HBV infection

Statins	HBV infectio	n		$\chi^2$	<i>P</i> -value
	negative	positive	Total (%)	χ	(two-sided)
no use (pre-admission)	2 (2.5%)	77 (97.5%)	79 (100%)	76.835	0.000
atorvastatin	134 (59.6%)	91 (40.4%)	225 (100%)		
rosuvastatin	88 (46.3%)	102 (53.7%)	190 (100%)		
total	224	270	494		
OR (no use/atorvastatin)	0.018	(95% CI: 0.004 t	76.904	0.000	
OR (no use/rosuvastatin)	0.030 (95% CI: 0.007 to 0.126)			48.048	0.000
OR (atorvastatin/rosuvastatin)	1.940	(95% CI: 1.280 t	to 2.940)	9.979	0.002

Table 3. Relationship between statin use and quantitative parameters of HBV

Variables	Statins use	N	P50 (P25 – P75)	Mean ± SD	Range
HBsAg	No use=0	79	>250 (26 to >250)		<0.05 to >250
	atorvastatin =1	225	<0.05(<0.05 to 129)		<0.05 to >250
	rosuvastatin=2	190	2(<0.05 to 174)		<0.05 to >250
	measure		H = 65.606		
	P		0.000		
Median Differe	ence(0-1)		70(95% CI: 26 to 125)		
Median Differe	ence(0-2)		63(95% CI: 18 to 117)		
Median Differe	ence(1-2)		0(95% CI: 0 to 0)		
HBsAb	No use=0	73	0.58(0.20 to 1.45)	2.4±7.9	0 to 52
	atorvastatin =1	199	2.10(0.58 to 20.97)	48±133	0 to 951
	rosuvastatin=2	181	1.31(0.43 to 5.98)	21±57	0 to 338
	measure		H = 31.257		
	P		0.000		
HBeAg	No use=0	73	0.34(0.31 to 0.42)	0.68±2.18	0.01 to 19
	atorvastatin =1	214	0.39(0.34 to 0.43)	9±111	0.01 to 1617
	rosuvastatin=2	186	0.39(0.34 to 0.43)	26±175	0.0225 to 1438
	measure		H = 8.044		
	P		0.018		
HBeAb	No use=0	73	0.01(0.01 to 0.02)	0.20±0.48	0.01 to 2
	atorvastatin =1	214	0.86(0.02 to 1.76)	1.17±3.07	0 to 43
	rosuvastatin=2	186	0.47(0.01 to 1.74)	1.75±6.27	0.01 to 51
	measure		H = 47.239		
	P		0.000		
HBcAb	No use=0	73	7.89(7.09 to 8.61)	7.69±1.57	0.06 to 10
	atorvastatin =1	214	6.06(0.16 to 7.62)	4.65±3.46	0.04 to 11
	rosuvastatin=2	186	7.02(0.62 to 8.04)	5.26±3.53	0.03 to 11
	measure		H = 47.295		
	P		0.000		
HBV DNA	No use=0	42	129(<100 to 2103)		<10 to 11800000
	atorvastatin =1	121	<100(<100 to <100)		<10 to 1310000
	rosuvastatin=2	111	<100(<100 to <100)		<10 to 476000000
	measure		H = 5.522		

medRxiv preprint doi: https://doi.org/10.1101/2024.11.05.24316797; this version posted November 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license.

P	0.063	

Table 4. Relationship between statin dose and HbsAg quantification.

Statins use		HbsAg quantificat	J-T	P (two-sided)	
Statilis use	N	N P50(P25–P75) Range			
no use (pre-admission)	79	251(26 to >250)	<0.05 to >250		
atorvastatin (10 mg)	19	78(<0.05 to >250)	<0.05 to >250		
atorvastatin (20 mg)	182	<0.05 (<0.05 to 83)	<0.05 to >250		
atorvastatin (40 mg)	19	<0.05 (<0.05 to >250)	<0.05 to >250	-7.615	0.000
rosuvastatin (10 mg)	8	17(<0.05 to 198)	<0.05 to >250		
rosuvastatin (20 mg)	166	1(<0.05 to 112)	<0.05 to >250		
rosuvastatin (40 mg)	12	80(<0.05 to >250)	<0.05 to >250	-5.936	0.000